The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 01, 2008

Filed:

Jan. 07, 2004
Applicants:

Pascal Chaux, Marcy l'Etoile, FR;

Rosalie Luiten, Amsterdam, NL;

Nathalie Demotte, Brussels, BE;

Marie-therese Duffour, Saint-Denis cedex, FR;

Christophe Lurquin, Brussels, BE;

Catie Traversari, Milan, IT;

Vincent Stroobant, Brussels, BE;

Guy R. Cornelis, Basel, CH;

Thierry Boon-falleur, Brussels, BE;

Pierre Van Der Bruggen, Brussels, BE;

Erwin Schultz, Marburg, DE;

Guy Warnier, Brussels, BE;

Inventors:

Pascal Chaux, Marcy l'Etoile, FR;

Rosalie Luiten, Amsterdam, NL;

Nathalie Demotte, Brussels, BE;

Marie-Therese Duffour, Saint-Denis cedex, FR;

Christophe Lurquin, Brussels, BE;

Catie Traversari, Milan, IT;

Vincent Stroobant, Brussels, BE;

Guy R. Cornelis, Basel, CH;

Thierry Boon-Falleur, Brussels, BE;

Pierre van der Bruggen, Brussels, BE;

Erwin Schultz, Marburg, DE;

Guy Warnier, Brussels, BE;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 63/00 (2006.01); C12N 5/08 (2006.01); A61K 39/00 (2006.01); A61K 38/04 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant, recombinant, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.


Find Patent Forward Citations

Loading…